{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T15:50:34Z","timestamp":1793029834553,"version":"4.5.0"},"reference-count":128,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.eplepsyres.2022.107041","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T21:59:37Z","timestamp":1667080777000},"page":"107041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"special_numbering":"C","title":["Dravet syndrome: Advances in etiology, clinical presentation, and treatment"],"prefix":"10.1016","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-1504","authenticated-orcid":false,"given":"Zimeng","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baomin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.eplepsyres.2022.107041_bib1","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM198511283132219","article-title":"Treatment of self-induced photosensitive epilepsy with fenfluramine","volume":"313","author":"Aicardi","year":"1985","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1528-1167.2009.02466.x","article-title":"A long-term follow-up study of Dravet syndrome up to adulthood","volume":"51","author":"Akiyama","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib3","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1111\/epi.13692","article-title":"Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features","volume":"58","author":"Aljaafari","year":"2017","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib4","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1528-1167.2009.02408.x","article-title":"Dravet syndrome and deep brain stimulation: seizure control after 10 years of treatment","volume":"51","author":"Andrade","year":"2010","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/ana.24596","article-title":"Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy","volume":"79","author":"Bagnall","year":"2016","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib6","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/epi.12658","article-title":"Co-occurring malformations of cortical development and SCN1A gene mutations","volume":"55","author":"Barba","year":"2014","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib7","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1535759719858339","article-title":"Beyond Dravet syndrome: characterization of a novel, more severe SCN1A-Linked epileptic encephalopathy","volume":"19","author":"Beck","year":"2019","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib8","first-page":"Aug 11","article-title":"Progress report on new antiepileptic drugs: a summary of the Sixteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVI): II","author":"Bialer","year":"2022","journal-title":"Drugs More Adv. Clin. Dev. Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2007-973781","article-title":"Add-on therapy of fenfluramine in intractable self-induced epilepsy","volume":"27","author":"Boel","year":"1996","journal-title":"Neuropediatrics"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107041_bib10","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/j.1528-1167.2011.03129.x","article-title":"Comorbidities and predictors of health-related quality of life in Dravet syndrome","volume":"52","author":"Brunklaus","year":"2011","journal-title":"Epilepsia"},{"issue":"Pt 8","key":"10.1016\/j.eplepsyres.2022.107041_bib11","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1093\/brain\/aws151","article-title":"Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome","volume":"135","author":"Brunklaus","year":"2012","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib12","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejpn.2015.02.001","article-title":"Homozygous mutations in the SCN1A gene associated with genetic epilepsy with febrile seizures plus and Dravet syndrome in 2 families","volume":"19","author":"Brunklaus","year":"2015","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2022.107041_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1528-1167.2011.02996.x","article-title":"Electroencephalographic characteristics of Dravet syndrome","volume":"52","author":"Bureau","year":"2011","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2022.107041_bib14","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1528-1167.2011.03009.x","article-title":"Nonpharmacologic treatments of Dravet syndrome: focus on the ketogenic diet","volume":"52","author":"Caraballo","year":"2011","journal-title":"Epilepsia"},{"issue":"14","key":"10.1016\/j.eplepsyres.2022.107041_bib15","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1212\/WNL.0000000000000291","article-title":"GABRA1 and STXBP1: novel genetic causes of Dravet syndrome","volume":"82","author":"Carvill","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ajhg.2018.10.023","article-title":"Aberrant Inclusion of a Poison exon causes dravet syndrome and related SCN1A-Associated genetic epilepsies","volume":"103","author":"Carvill","year":"2018","journal-title":"Am. J. Hum. Genet"},{"issue":"Pt 11","key":"10.1016\/j.eplepsyres.2022.107041_bib17","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1113\/jphysiol.2010.187484","article-title":"NaV1.1 channels and epilepsy","volume":"588","author":"Catterall","year":"2010","journal-title":"J. Physiol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2022.107041_bib18","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1212\/WNL.0000000000003716","article-title":"Clinical and genetic factors predicting Dravet syndrome in infants with SCN1A mutations","volume":"88","author":"Cetica","year":"2017","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib19","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107041_bib20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/S1474-4422(08)70141-8","article-title":"Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study","volume":"7","author":"Chin","year":"2008","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib21","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.seizure.2010.01.007","article-title":"Unusual consequences of status epilepticus in Dravet syndrome","volume":"19","author":"Chipaux","year":"2010","journal-title":"Seizure"},{"issue":"9242","key":"10.1016\/j.eplepsyres.2022.107041_bib22","first-page":"1638","article-title":"Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial","volume":"356","author":"Chiron","year":"2000","journal-title":"STICLO Study Group. Lancet"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/320609","article-title":"De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy","volume":"68","author":"Claes","year":"2001","journal-title":"Am. J. Hum. Genet"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib24","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2022.107041_bib25","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/cjn.2016.243","article-title":"Dravet syndrome: diagnosis and long-term course","volume":"43","author":"Connolly","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.eplepsyres.2016.10.006","article-title":"Mortality in Dravet syndrome","volume":"128","author":"Cooper","year":"2016","journal-title":"Epilepsy Res."},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2022.107041_bib27","first-page":"S39","article-title":"Dravet syndrome: Treatment options and management of prolonged seizures","volume":"60","author":"Cross","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib28","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.seizure.2021.10.024","article-title":"Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome","volume":"93","author":"Cross","year":"2021","journal-title":"Seizure Dec."},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2022.107041_bib29","first-page":"S49","article-title":"Dravet syndrome: early electroclinical findings and long-term outcome in adolescents and adults","volume":"60","author":"Darra","year":"2019","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.eplepsyres.2022.107041_bib30","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.eplepsyres.2022.107041_bib31","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1212\/WNL.0000000000005254","article-title":"Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome","volume":"90","author":"Devinsky","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107041_bib32","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib33","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/acn3.51306","article-title":"Ataluren for drug-resistant epilepsy in nonsense variant-mediated Dravet syndrome and CDKL5 deficiency disorder","volume":"8","author":"Devinsky","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2022.107041_bib34","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.pediatrneurol.2014.01.017","article-title":"Sleep abnormalities in children with Dravet syndrome","volume":"50","author":"Dhamija","year":"2014","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib35","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.seizure.2017.06.007","article-title":"Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: a meta-analysis of 68 patients","volume":"50","author":"Dibu\u00e9-Adjei","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.743726","article-title":"SCN1A mutation-beyond Dravet syndrome: a systematic review and narrative synthesis","volume":"12","author":"Ding","year":"2021","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/mgg3.217","article-title":"Pitfalls in genetic testing: the story of missed SCN1A mutations","volume":"4","author":"Dj\u00e9mi\u00e9","year":"2016","journal-title":"Mol. Genet Genom. Med."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib38","first-page":"543","article-title":"Les epilepsies graves de l\u2032enfant","volume":"8","author":"Dravet","year":"1978","journal-title":"Vie m\u00e9d"},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2022.107041_bib39","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.02994.x","article-title":"The core Dravet syndrome phenotype","volume":"52","author":"Dravet","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2014.10.014","article-title":"Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen","volume":"109","author":"Dressler","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib41","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.nbd.2012.08.012","article-title":"Preferential inactivation of Scn1a in parvalbumin interneurons increases seizure susceptibility","volume":"49","author":"Dutton","year":"2013","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107041_bib42","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1111\/j.1528-1167.2010.02640.x","article-title":"Sodium channel SCN1A and epilepsy: mutations and mechanisms","volume":"51","author":"Escayg","year":"2010","journal-title":"Epilepsia"},{"issue":"24","key":"10.1016\/j.eplepsyres.2022.107041_bib43","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1212\/WNL.0000000000000521","article-title":"Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome","volume":"82","author":"Fasano","year":"2014","journal-title":"Neurology"},{"issue":"36","key":"10.1016\/j.eplepsyres.2022.107041_bib44","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.1523\/JNEUROSCI.0193-18.2018","article-title":"A transient developmental window of fast-spiking interneuron dysfunction in a mouse model of dravet syndrome","volume":"38","author":"Favero","year":"2018","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib45","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","article-title":"The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator","volume":"56","author":"Fisher","year":"2009","journal-title":"Neuropharmacology"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107041_bib46","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2022.107041_bib47","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","article-title":"Dravet syndrome: the long-term outcome","volume":"52","author":"Genton","year":"2011","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib48","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","article-title":"In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism","volume":"34","author":"Giraud","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib49","first-page":"669","article-title":"Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome","volume":"140","author":"Griffin","year":"2017","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib50","doi-asserted-by":"crossref","first-page":"fcz008","DOI":"10.1093\/braincomms\/fcz008","article-title":"Zebrafish studies identify serotonin receptors mediating antiepileptic activity in Dravet syndrome","volume":"1","author":"Griffin","year":"2019","journal-title":"Brain Commun."},{"issue":"5","key":"10.1016\/j.eplepsyres.2022.107041_bib51","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","article-title":"Lamotrigine and seizure aggravation in severe myoclonic epilepsy","volume":"39","author":"Guerrini","year":"1998","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib52","first-page":"8","article-title":"An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real-world practice setting: a report from the Fenfluramine European Early Access Program","author":"Guerrini","year":"2022","journal-title":"Epilepsia Open. Jul."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib53","first-page":"16","article-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","author":"Hahn","year":"2022","journal-title":"Epilepsia Jul."},{"issue":"558","key":"10.1016\/j.eplepsyres.2022.107041_bib54","doi-asserted-by":"crossref","first-page":"eaaz6100","DOI":"10.1126\/scitranslmed.aaz6100","article-title":"Antisense oligonucleotides increase Scn1a expression and reduce seizures and SUDEP incidence in a mouse model of Dravet syndrome","volume":"12","author":"Han","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"Pt 3","key":"10.1016\/j.eplepsyres.2022.107041_bib55","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1093\/brain\/awm002","article-title":"The spectrum of SCN1A-related infantile epileptic encephalopathies","volume":"130","author":"Harkin","year":"2007","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib56","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1528-1167.2007.01475.x","article-title":"A screening test for the prediction of Dravet syndrome before one year of age","volume":"49","author":"Hattori","year":"2008","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107041_bib57","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcab033","article-title":"Dravet syndrome-associated mutations in GABRA1, GABRB2 and GABRG2 define the genetic landscape of defects of GABAA receptors","volume":"3","author":"Hernandez","year":"2021","journal-title":"Brain Commun."},{"issue":"12","key":"10.1016\/j.eplepsyres.2022.107041_bib58","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1212\/01.wnl.0000249312.73155.7d","article-title":"Severe myoclonic epilepsy of infancy (Dravet syndrome): recognition and diagnosis in adults","volume":"67","author":"Jansen","year":"2006","journal-title":"Neurology"},{"issue":"41","key":"10.1016\/j.eplepsyres.2022.107041_bib59","doi-asserted-by":"crossref","first-page":"11065","DOI":"10.1523\/JNEUROSCI.2162-07.2007","article-title":"Reduced sodium current in Purkinje neurons from Nav1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy","volume":"27","author":"Kalume","year":"2007","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib60","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1172\/JCI66220","article-title":"Sudden unexpected death in a mouse model of Dravet syndrome","volume":"123","author":"Kalume","year":"2013","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib61","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.clinph.2014.06.024","article-title":"Ictal ontogeny in Dravet syndrome","volume":"126","author":"Kim","year":"2015","journal-title":"Clin. Neurophysiol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib62","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/dmcn.13591","article-title":"Quality of life and comorbidities associated with Dravet syndrome severity: a multinational cohort survey","volume":"60","author":"Lagae","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"10216","key":"10.1016\/j.eplepsyres.2022.107041_bib63","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib64","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/epi.14021","article-title":"Mosaicism of de novo pathogenic SCN1A variants in epilepsy is a frequent phenomenon that correlates with variable phenotypes","volume":"59","author":"de Lange","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib65","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/epi.14191","article-title":"Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A-related seizure phenotypes","volume":"59","author":"de Lange","year":"2018","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107041_bib66","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1002\/ajmg.a.38282","article-title":"A mutation in GABRB3 associated with Dravet syndrome","volume":"173","author":"Le","year":"2017","journal-title":"Am. J. Med. Genet A"},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107041_bib67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/epi.13964","article-title":"Deep brain stimulation for drug-resistant epilepsy","volume":"59","author":"Li","year":"2018","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107041_bib68","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1111\/epi.17015","article-title":"Defining Dravet syndrome: an essential pre-requisite for precision medicine trials","volume":"62","author":"Li","year":"2021","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107041_bib69","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/dmcn.13601","article-title":"Sleep problems in Dravet syndrome: a modifiable comorbidity","volume":"60","author":"Licheni","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib70","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13041-018-0392-5","article-title":"Novel and de novo mutations in pediatric refractory epilepsy","volume":"11","author":"Liu","year":"2018","journal-title":"Mol. Brain"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib71","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.yebeh.2017.05.037","article-title":"Age-related \"Sleep\/nocturnal\" tonic and tonic clonic seizure clusters are underdiagnosed in patients with Dravet syndrome","volume":"74","author":"Losito","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib72","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1055\/s-0032-1307454","article-title":"Bromide in patients with SCN1A-mutations manifesting as Dravet syndrome","volume":"43","author":"Lotte","year":"2012","journal-title":"Neuropediatrics"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib73","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1111\/j.1528-1167.2009.02013.x","article-title":"SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis","volume":"50","author":"Marini","year":"2009","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"10.1016\/j.eplepsyres.2022.107041_bib74","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1528-1167.2011.02997.x","article-title":"The genetics of Dravet syndrome","volume":"52","author":"Marini","year":"2011","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib75","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S1474-4422(10)70107-1","article-title":"Effects of vaccination on onset and outcome of Dravet syndrome: a retrospective study","volume":"9","author":"McIntosh","year":"2010","journal-title":"Lancet Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2022.107041_bib76","first-page":"S2","article-title":"Dravet syndrome as part of the clinical and genetic spectrum of sodium channel epilepsies and encephalopathies","volume":"60","author":"Mei","year":"2019","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib77","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/humu.22782","article-title":"The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype","volume":"36","author":"Meng","year":"2015","journal-title":"Hum. Mutat."},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107041_bib78","doi-asserted-by":"crossref","first-page":"785","DOI":"10.3390\/ph14080785","article-title":"Ataluren-promising therapeutic premature termination codon readthrough frontrunner","volume":"14","author":"Michorowska","year":"2021","journal-title":"Pharmaceuticles"},{"issue":"5","key":"10.1016\/j.eplepsyres.2022.107041_bib79","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib80","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejpn.2021.05.018","article-title":"SCN1A-related epilepsy with recessive inheritance: two further families","volume":"33","author":"Moretti","year":"2021","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib81","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/jcpt.12659","article-title":"Marked efficacy of combined three-drug therapy (Sodium Valproate, Topiramate and Stiripentol) in a patient with Dravet syndrome","volume":"43","author":"Morimoto","year":"2018","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib82","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pediatrneurol.2017.01.004","article-title":"Myoclonic absence seizures in Dravet syndrome","volume":"70","author":"Myers","year":"2017","journal-title":"Pedia Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib83","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study","volume":"60","author":"Myers","year":"2018","journal-title":"Dev. Med Child Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib84","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2008.04.015","article-title":"An unexpected EEG course in Dravet syndrome","volume":"81","author":"Nabbout","year":"2008","journal-title":"Epilepsy Res."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib85","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib86","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2013.09.009","article-title":"Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study","volume":"23","author":"Nicita","year":"2014","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107041_bib87","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1017\/S0012162206001629","article-title":"Coping with Dravet syndrome: parental experiences with a catastrophic epilepsy","volume":"48","author":"Nolan","year":"2006","journal-title":"Dev. Med. Child Neurol."},{"issue":"22","key":"10.1016\/j.eplepsyres.2022.107041_bib88","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1523\/JNEUROSCI.5270-06.2007","article-title":"Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an Scn1a gene mutation","volume":"27","author":"Ogiwara","year":"2007","journal-title":"J. Neurosci."},{"issue":"6","key":"10.1016\/j.eplepsyres.2022.107041_bib89","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1157.1994.tb01780.x","article-title":"Treatment of severe myoclonic epilepsy in infants with bromide and its borderline variant","volume":"35","author":"Oguni","year":"1994","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib90","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/epi.12762","article-title":"Vagus nerve stimulation for drug-resistant epilepsy: a European long-term study up to 24 months in 347 children","volume":"55","author":"Orosz","year":"2014","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib91","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1001\/archneurol.2011.3275","article-title":"Progressive gait deterioration in adolescents with Dravet syndrome","volume":"69","author":"Rodda","year":"2012","journal-title":"Arch. Neurol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib92","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1474-4422(13)70214-X","article-title":"Incidence and mechanisms of cardiorespiratory arrests in epilepsy monitoring units (MORTEMUS): a retrospective study","volume":"12","author":"Ryvlin","year":"2013","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib93","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1212\/WNL.0000000000004331","article-title":"Not all SCN1A epileptic encephalopathies are Dravet syndrome: Early profound Thr226Met phenotype","volume":"89","author":"Sadleir","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.eplepsyres.2022.107041_bib94","doi-asserted-by":"crossref","first-page":"zsz173","DOI":"10.1093\/sleep\/zsz173","article-title":"Circadian regulation of sleep in a pre-clinical model of Dravet syndrome: dynamics of sleep stage and siesta re-entrainment","volume":"42","author":"Sanchez","year":"2019","journal-title":"Sleep"},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2022.107041_bib95","first-page":"S17","article-title":"SCN1A-related phenotypes: epilepsy and beyond","volume":"60","author":"Scheffer","year":"2019","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib96","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib97","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/epi.17036","article-title":"Add-on cannabidiol in patients with Dravet syndrome: results of a long-term open-label extension trial","volume":"62","author":"Scheffer","year":"2021","journal-title":"Epilepsia Oct."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107041_bib98","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/ene.13195","article-title":"Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients","volume":"24","author":"Schoonjans","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib99","first-page":"1","article-title":"A critical evaluation of fenfluramine hydrochloride for the treatment of Dravet syndrome","volume":"26","author":"Schoonjans","year":"2021","journal-title":"Expert Rev. Neurother."},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib100","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejpn.2018.09.012","article-title":"More daytime sleepiness and worse quality of sleep in patients with Dravet Syndrome compared to other epilepsy patients","volume":"23","author":"Schoonjans","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"Pt A","key":"10.1016\/j.eplepsyres.2022.107041_bib101","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yebeh.2019.06.021","article-title":"Seizure management and prescription patterns of anticonvulsants in Dravet syndrome: a multicenter cohort study from Germany and review of literature","volume":"98","author":"Schubert-Bast","year":"2019","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib102","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1399-0004.2009.01208.x","article-title":"Parental SCN1A mutation mosaicism in familial Dravet syndrome","volume":"76","author":"Selmer","year":"2009","journal-title":"Clin. Genet"},{"issue":"Pt A","key":"10.1016\/j.eplepsyres.2022.107041_bib103","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.yebeh.2016.09.007","article-title":"Mortality in Dravet syndrome: a review","volume":"64","author":"Shmuely","year":"2016","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.eplepsyres.2022.107041_bib104","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/0883073811419262","article-title":"Electroencephalographic features in dravet syndrome: five-year follow-up study in 22 patients","volume":"27","author":"Specchio","year":"2012","journal-title":"J. Child Neurol."},{"issue":"11","key":"10.1016\/j.eplepsyres.2022.107041_bib105","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1111\/epi.13889","article-title":"Dravet syndrome and its mimics: Beyond SCN1A","volume":"58","author":"Steel","year":"2017","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib106","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs Mar."},{"issue":"3","key":"10.1016\/j.eplepsyres.2022.107041_bib107","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ejpn.2019.02.014","article-title":"Burden-of-illness and cost-driving factors in Dravet syndrome patients and carers: a prospective, multicenter study from Germany","volume":"23","author":"Strzelczyk","year":"2019","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib108","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1111\/epi.17034","article-title":"Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: compassionate use program in Germany","volume":"62","author":"Strzelczyk","year":"2021","journal-title":"Epilepsia Oct."},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib109","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.braindev.2008.03.002","article-title":"Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome)--a nationwide questionnaire survey in Japan","volume":"30","author":"Tanabe","year":"2008","journal-title":"Brain Dev."},{"issue":"18","key":"10.1016\/j.eplepsyres.2022.107041_bib110","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.0000000000006432","article-title":"Lorcaserin therapy for severe epilepsy of childhood onset: a case series","volume":"91","author":"Tolete","year":"2018","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib111","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1177\/0883073811435325","article-title":"Mesial temporal sclerosis in a cohort of children with SCN1A gene mutation","volume":"27","author":"Van Poppel","year":"2012","journal-title":"J. Child Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2022.107041_bib112","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.clinph.2016.11.021","article-title":"Photosensitivity in Dravet syndrome is under-recognized and related to prognosis","volume":"128","author":"Verbeek","year":"2017","journal-title":"Clin. Neurophysiol."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib113","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.yebeh.2015.05.008","article-title":"Seizure precipitants in Dravet syndrome: what events and activities are specifically provocative compared with other epilepsies","volume":"47","author":"Verbeek","year":"2015","journal-title":"Epilepsy Behav."},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib114","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1212\/WNL.0000000000001855","article-title":"Effect of vaccinations on seizure risk and disease course in Dravet syndrome","volume":"85","author":"Verbeek","year":"2015","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.eplepsyres.2022.107041_bib115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/dmcn.14147","article-title":"Motor development in children with Dravet syndrome","volume":"61","author":"Verheyen","year":"2019","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib116","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2017.06.031","article-title":"Dravet syndrome: characteristics, comorbidities, and caregiver concerns","volume":"74","author":"Villas","year":"2017","journal-title":"Epilepsy Behav. Sep"},{"issue":"1","key":"10.1016\/j.eplepsyres.2022.107041_bib117","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1009195","article-title":"Aberrant regulation of a poison exon caused by a non-coding variant in a mouse model of Scn1a-associated epileptic encephalopathy","volume":"17","author":"Voskobiynyk","year":"2021","journal-title":"PLoS Genet"},{"issue":"10","key":"10.1016\/j.eplepsyres.2022.107041_bib118","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1528-1157.1996.tb00542.x","article-title":"\"Obtundation status (Dravet)\" caused by complex partial status epilepticus in a patient with severe myoclonic epilepsy in infancy","volume":"37","author":"Wakai","year":"1996","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107041_bib119","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1528-1167.2008.01609.x","article-title":"Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy","volume":"49","author":"Wang","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib120","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.brainres.2011.02.083","article-title":"The developmental changes of Na(v)1.1 and Na(v)1.2 expression in the human hippocampus and temporal lobe","volume":"1389","author":"Wang","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.seizure.2020.07.011","article-title":"Efficacy of the ketogenic diet in patients with Dravet syndrome: a meta-analysis","volume":"81","author":"Wang","year":"2020","journal-title":"Seizure"},{"issue":"Suppl 3","key":"10.1016\/j.eplepsyres.2022.107041_bib122","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1017\/cjn.2016.249","article-title":"Treatment of Dravet syndrome","volume":"43","author":"Wirrell","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107041_bib123","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/epi.12303","article-title":"Stiripentol in Dravet syndrome: results of a retrospective U.S. study","volume":"54","author":"Wirrell","year":"2013","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib124","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1111\/epi.17274","article-title":"International consensus on diagnosis and management of Dravet syndrome","volume":"63","author":"Wirrell","year":"2022","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.eplepsyres.2022.107041_bib125","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/humu.22819","article-title":"Amplicon resequencing identified parental mosaicism for approximately 10\u00a0% of \"de novo\" SCN1A mutations in children with Dravet syndrome","volume":"36","author":"Xu","year":"2015","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.eplepsyres.2022.107041_bib126","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.seizure.2018.06.023","article-title":"Prospective study of the efficacy of a ketogenic diet in 20 patients with Dravet syndrome","volume":"60","author":"Yan","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2022.107041_bib127","unstructured":"Young A.N. , Tanenhaus A. , Belle A. , 2019. A GABA-selective AAV vector upregulates endogenous SCN1A expression and reverses multiple phenotypes in a mouse model of Dravet syndrome. 73rd American Epilepsy Society Annual Meeting."},{"issue":"7","key":"10.1016\/j.eplepsyres.2022.107041_bib128","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1212\/WNL.0b013e31820c309b","article-title":"Genotype-phenotype associations in SCN1A-related epilepsies","volume":"76","author":"Zuberi","year":"2011","journal-title":"Neurology"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121122001929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:49:03Z","timestamp":1760276943000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121122001929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":128,"alternative-id":["S0920121122001929"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107041","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dravet syndrome: Advances in etiology, clinical presentation, and treatment","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2022.107041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107041"}}